FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3020717248> ?p ?o ?g. }

• W3020717248 endingPage "309" @default.
• W3020717248 startingPage "308" @default.
• W3020717248 abstract "Abstract: Background: Dasotraline is a long-acting dopamine/norepinephrine reuptake inhibitor with a PK profile characterized by slow absorption and a t½ of 47-77 hours, permitting once-daily dosing. In a previous flexible dose study, dasotraline demonstrated significant efficacy in the treatment of binge-eating disorder (BED). The aim of this confirmatory fixed-dose study was to evaluate efficacy and safety of dasotraline in the treatment of patients with BED. Methods: Patients meeting DSM-5 criteria for BED were randomized to 12 weeks of double-blind treatment with dasotraline (4 mg/d or 6 mg/d), or placebo. The primary efficacy endpoint was change in number of binge-eating days per week at week 12. Secondary efficacy endpoints included changes at Week 12 on the Binge Eating Clinical Global Impression of Severity Scale (BE-CGI-S), the Yale-Brown Obsessive-Compulsive Scale Modified for Binge Eating (Y-BOCS-BE), and the proportion of patients with 100% cessation of binge-eating episodes during the final 4 weeks of treatment. Efficacy was assessed using an MMRM analysis (and a logistic regression model for cessation) with a pre-specified sequential testing procedure used to control overall type I error rate. Results: A total of 486 were in the ITT population (dasotraline 6 mg/d (N=162), 4 mg/d (N=161), or placebo (N=163). At week 12, treatment with dasotraline was associated with significant reduction in number of binge-eating days per week in the 6 mg/d group vs. placebo (-3.5 vs. -2.9; P=0.0045), but non-significant improvement in the 4 mg/d group vs. placebo (-3.2; P=0.12). Greater improvement was observed vs. placebo for dasotraline 6 mg/d and 4 mg/d, respectively, on the BE-CGI-S (P<0.01 and P<0.03) and the Y-BOC-BE (P<0.001 and P<0.02; all P-values were nominal, not adjusted for multiplicity). The proportion of patients who achieved 4-week cessation of binge-eating episodes was only significant for the dasotraline 6 mg in the completer population (P<0.05; post-hoc analysis) but was not significant for either dose of dasotraline vs. placebo when drop-outs were included in the analysis. The most common adverse events on dasotraline 6 mg/d and 4 mg/d were combined insomnia (early, middle, late), dry mouth, headache, decreased appetite, nausea, and anxiety. Changes in systolic and diastolic blood pressure were minimal. Mean baseline to endpoint changes in supine pulse rate on dasotraline 6 mg/d and 4 mg/d vs. placebo was +6.2 bpm and +4.8 vs. +0.2 bpm. Conclusions: In this 12-week, placebo-controlled, fixed-dose study, treatment with dasotraline 6 mg/d was associated with a significant reduction in frequency of binge-eating days per week; efficacy was not demonstrated for the 4 mg dose. Treatment with both doses of dasotraline resulted in improvement in the Y-BOCS-BE and the BE-CGI-S. Dasotraline was safe and generally well-tolerated at both doses; most common adverse events were insomnia, dry mouth and headache. Clinicaltrials.gov: NCT03107026 Funding Acknowledgements: Supported by funding from Sunovion Pharmaceuticals Inc." @default.
• W3020717248 created "2020-05-01" @default.
• W3020717248 creator A5008221825 @default.
• W3020717248 creator A5015863768 @default.
• W3020717248 creator A5019090390 @default.
• W3020717248 creator A5029131403 @default.
• W3020717248 creator A5062341708 @default.
• W3020717248 creator A5066553937 @default.
• W3020717248 creator A5074806044 @default.
• W3020717248 creator A5079329164 @default.
• W3020717248 creator A5079968486 @default.
• W3020717248 date "2020-04-01" @default.
• W3020717248 modified "2023-09-24" @default.
• W3020717248 title "170 Efficacy and Safety of Dasotraline in Adults with Binge-Eating Disorder: A Randomized, Double-blind, Fixed-dose Trial" @default.
• W3020717248 doi "https://doi.org/10.1017/s1092852920000863" @default.
• W3020717248 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32331033" @default.
• W3020717248 hasPublicationYear "2020" @default.
• W3020717248 type Work @default.
• W3020717248 sameAs 3020717248 @default.
• W3020717248 citedByCount "1" @default.
• W3020717248 countsByYear W30207172482021 @default.
• W3020717248 crossrefType "journal-article" @default.
• W3020717248 hasAuthorship W3020717248A5008221825 @default.
• W3020717248 hasAuthorship W3020717248A5015863768 @default.
• W3020717248 hasAuthorship W3020717248A5019090390 @default.
• W3020717248 hasAuthorship W3020717248A5029131403 @default.
• W3020717248 hasAuthorship W3020717248A5062341708 @default.
• W3020717248 hasAuthorship W3020717248A5066553937 @default.
• W3020717248 hasAuthorship W3020717248A5074806044 @default.
• W3020717248 hasAuthorship W3020717248A5079329164 @default.
• W3020717248 hasAuthorship W3020717248A5079968486 @default.
• W3020717248 hasBestOaLocation W30207172481 @default.
• W3020717248 hasConcept C118552586 @default.
• W3020717248 hasConcept C126322002 @default.
• W3020717248 hasConcept C142724271 @default.
• W3020717248 hasConcept C168563851 @default.
• W3020717248 hasConcept C204787440 @default.
• W3020717248 hasConcept C27081682 @default.
• W3020717248 hasConcept C2776000289 @default.
• W3020717248 hasConcept C2776394216 @default.
• W3020717248 hasConcept C2777288759 @default.
• W3020717248 hasConcept C2777556793 @default.
• W3020717248 hasConcept C2778202721 @default.
• W3020717248 hasConcept C2781426410 @default.
• W3020717248 hasConcept C2908647359 @default.
• W3020717248 hasConcept C71924100 @default.
• W3020717248 hasConcept C99454951 @default.
• W3020717248 hasConceptScore W3020717248C118552586 @default.
• W3020717248 hasConceptScore W3020717248C126322002 @default.
• W3020717248 hasConceptScore W3020717248C142724271 @default.
• W3020717248 hasConceptScore W3020717248C168563851 @default.
• W3020717248 hasConceptScore W3020717248C204787440 @default.
• W3020717248 hasConceptScore W3020717248C27081682 @default.
• W3020717248 hasConceptScore W3020717248C2776000289 @default.
• W3020717248 hasConceptScore W3020717248C2776394216 @default.
• W3020717248 hasConceptScore W3020717248C2777288759 @default.
• W3020717248 hasConceptScore W3020717248C2777556793 @default.
• W3020717248 hasConceptScore W3020717248C2778202721 @default.
• W3020717248 hasConceptScore W3020717248C2781426410 @default.
• W3020717248 hasConceptScore W3020717248C2908647359 @default.
• W3020717248 hasConceptScore W3020717248C71924100 @default.
• W3020717248 hasConceptScore W3020717248C99454951 @default.
• W3020717248 hasIssue "2" @default.
• W3020717248 hasLocation W30207172481 @default.
• W3020717248 hasOpenAccess W3020717248 @default.
• W3020717248 hasPrimaryLocation W30207172481 @default.
• W3020717248 hasRelatedWork W2276633583 @default.
• W3020717248 hasRelatedWork W2618716238 @default.
• W3020717248 hasRelatedWork W2765566375 @default.
• W3020717248 hasRelatedWork W2917443406 @default.
• W3020717248 hasRelatedWork W3125983720 @default.
• W3020717248 hasRelatedWork W3196536608 @default.
• W3020717248 hasRelatedWork W4251572202 @default.
• W3020717248 hasRelatedWork W4317494831 @default.
• W3020717248 hasRelatedWork W187236902 @default.
• W3020717248 hasRelatedWork W2181726176 @default.
• W3020717248 hasVolume "25" @default.
• W3020717248 isParatext "false" @default.
• W3020717248 isRetracted "false" @default.
• W3020717248 magId "3020717248" @default.
• W3020717248 workType "article" @default.